Abstract
mPGES-1 is a terminal rate-limiting enzyme responsible for inflammation-induced PGE2 production. The inhibition of mPGES-1 has been considered as a safe and effective target for the treatment of inflammation and cancer. However, a specific, efficient, and simple method for high-throughput screening of mPGES-1 inhibitors is still lacking. In this study, we developed a fluorescence imaging strategy to monitor the expression of mPGES-1 via CRISPR/Cas9 knock-in system. Immunofluorescence colocalisation, Sanger sequencing, RNAi, and IL-1β treatment all confirmed the successful construction of mPGES-1 reporter cells. The fluorescence signal intensity of the reporter cells treated with four conventional mPGES-1 inhibitors was considerably attenuated via flow cytometry and fluorescent microplate reader, demonstrating that the reporter cells can be used as an efficient and convenient means for screening and optimising mPGES-1 inhibitors. Moreover, it provides a new technical support for the development of targeted small molecule compounds for anti-inflammatory and tumour therapy.
Author supplied keywords
Cite
CITATION STYLE
Chen, Z., Cai, X., Li, M., Yan, L. L., Wu, L., Wang, X., & Tang, N. (2019). CRISPR/Cas9-based liver-derived reporter cells for screening of mPGES-1 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 34(1), 799–807. https://doi.org/10.1080/14756366.2019.1587416
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.